This week's Fierce Biotech is brought to you by BioDuro-Sundia.

Webinar: Unleashing Innovation: A New Obesogenic NASH Model with High Clinically Translational Power

Monday, April 22, 2024 | 10:00am ET / 7:00am PT

Join us to explore cutting-edge NASH research with an innovative NAFLD/NASH animal model mirroring patient experiences. Dive into in vitro phenotypic models, utilizing human cells, and witness the effects of Resmetirom on inhibiting fat accumulation.

What to Expect: 

• Clinical Relevance: Aligns with trial studies for confident results.
• Quick Insights: Gain key NASH indicators in 12-16 weeks.
• Cost and Time Savings: Accelerated, target-specific assays save time and money.